VM BioPharma, the United States division of ViroMed Co., Ltd. in Seoul, Korea, announced the first patient was dosed in the recently initiated Phase 3 clinical study evaluating VM202, a proprietary DNA based biopharmaceutical, in patients with painful diabetic peripheral neuropathy (DPN). This is the first pivotal gene therapy trial specifically targeting the most common cause of severe neuropathy.
[minti_blockquote]”The initiation of a pivotal clinical trial for VM202 is incredibly exciting, because we observed in the Phase 2 trial a rapid and significant reduction in DPN pain, along with signals that VM202 may elicit a disease-modifying effect,” said Dr. Jack Kessler, M.D., professor of neurology at Northwestern University’s Feinberg School of Medicine and the principal investigator of the Phase 3 study (and former Board Member of the Foundation for Peripheral Neuropathy). “Current treatments for DPN are aimed at providing symptom management, and along with a high rate of patient failure, do not modify the underlying pathology of the condition.”[/minti_blockquote]
For more information about Diabetic Peripheral Neuropathy click here.